A Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy, Safety and Duration of Effect of a Single Administration of Various Doses of Cetrorelix SR in Subjects With Histologically Confirmed End
Completed
Solvay Pharmaceuticals
Phase 2
2005-11-01
Identify effective doses of cetrorelix SR in the treatment of symptoms of endometriosis,
describe dose effect relationship and duration of symptom relief
Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Terminated
AEterna Zentaris
Phase 3
2007-03-01
Benign Prostatic Hypertrophy (BPH) is a common and bothersome condition of aging men. It is
characterized by an enlargement of the prostate occurring in human male over the age of 50
which increases in prevalence with age, and among those aged 50 to 80, about 40% report
moderate or severe urinary symptoms of prostatism. The aim of treatment is to improve
patients' quality of life which primarily depends on the severity of the symptoms of BPH.
Current treatments of BPH have a benefit / risk ratio which leaves room for improvement.
For this study, study medication (Cetrorelix pamoate or placebo) is administered by injection
in the buttocks (Intramuscular). All patients completing the double-blind portion (Week 0 to
52) are eligible to receive the active drug during the open-label part of the study (Week 52
to 90).
GnRH Agonist and Antagonists in an Oocyte Donation Program
Completed
Instituto Valenciano de Infertilidad, IVI VALENCIA
Phase 4
1969-12-31
The primary purpose of this study is to evaluate the effect of the two different protocols
(long protocol vs antagonist protocol) on oocyte / embryo quality.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
